Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.

[1]  Miwako Kobayashi,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.

[2]  K. Jansen,et al.  Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides , 2018, mSphere.

[3]  Anouk M. Oordt-Speets,et al.  Global etiology of bacterial meningitis: A systematic review and meta-analysis , 2018, PloS one.

[4]  William A. Mattingly,et al.  Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  William A. Mattingly,et al.  Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Eyal Oren,et al.  Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Infectious diseases.

[7]  D. Greenberg,et al.  Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD. , 2016, Vaccine.

[8]  W. Schaffner,et al.  Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Cohen,et al.  The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014 , 2016, Human vaccines & immunotherapeutics.

[10]  C. Doit,et al.  Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. , 2015, Vaccine.

[11]  Ankita P. Desai,et al.  Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia , 2015, The Pediatric infectious disease journal.

[12]  E. Emini,et al.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. , 2015, Vaccine.

[13]  D. Greenberg,et al.  Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. , 2015, Vaccine.

[14]  D. Grobbee,et al.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. , 2015, The New England journal of medicine.

[15]  M. Westerink,et al.  Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic , 2015, Expert review of vaccines.

[16]  T. Welte,et al.  Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? , 2015, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[17]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.

[18]  S. Richter,et al.  Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States , 2014, Antimicrobial Agents and Chemotherapy.

[19]  K. Mølbak,et al.  Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  G. Rohde,et al.  Pneumococcal infection in adults: burden of disease. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  R. Cohen,et al.  Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  T. File,et al.  Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. , 2013, The Journal of infectious diseases.

[23]  E. Emini,et al.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. , 2013, Vaccine.

[24]  E. Emini,et al.  Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. , 2013, Vaccine.

[25]  D. Musher,et al.  Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: Results of a one-year study , 2013, Journal of Infection.

[26]  N. Andrews,et al.  Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. , 2012, Vaccine.

[27]  N. Andrews,et al.  Effect of Serotype on Focus and Mortality of Invasive Pneumococcal Disease: Coverage of Different Vaccines and Insight into Non-Vaccine Serotypes , 2012, PloS one.

[28]  D. Cooper,et al.  The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. , 2011, Vaccine.

[29]  T. Lieu,et al.  Healthcare utilization and cost of pneumococcal disease in the United States. , 2011, Vaccine.

[30]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[31]  T. Cherian,et al.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates , 2009, The Lancet.

[32]  L. Jackson,et al.  Pneumococcal vaccination of elderly adults: new paradigms for protection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. Anzueto,et al.  A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. , 2008, Chest.

[34]  D. Feikin,et al.  Epidemiological differences among pneumococcal serotypes. , 2005, The Lancet. Infectious diseases.

[35]  A. Ortqvist,et al.  Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. , 2003, Vaccine.

[36]  K. Stein.  Thymus-independent and thymus-dependent responses to polysaccharide antigens. , 1992, The Journal of infectious diseases.

[37]  R. Adair,et al.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. , 1991, The New England journal of medicine.